Danish Electrical Stock News

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities. See our latest analysis for Zealand Pharma. The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum...

Regulatory update: EMA review for paediatric mpox and smallpox use Bavarian Nordic (CPSE:BAVA) has filed Phase 2 data with the European Medicines Agency to extend its MVA-BN mpox and smallpox vaccine indication to children aged 2 to 11. This filing highlights a potential shift in the product’s approved patient group. See our latest analysis for Bavarian Nordic. The latest EMA filing comes as Bavarian Nordic’s DKK195.7 share price sits on a 4.3% 1 month share price return and a 36.7% 1 year...

In late March 2026, Vestas Wind Systems announced a series of new wind turbine orders across Germany, France, the UK and the USA, alongside long-term service agreements and deliveries stretching from 2026 to 2028, and separately revealed plans for a more than €250 million nacelle and hub factory in Scotland targeting its V236-15.0 MW offshore turbines. Taken together, the fresh onshore order intake and the conditional Scottish offshore factory plan underline how Vestas is tying near-term...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

What the latest debt redemption and AGM changes mean for NKT stock NKT (CPSE:NKT) plans to redeem all remaining securities on 20 April 2026 after buying back most of the originally issued amount, while also reshaping its governance framework at the recent Annual General Meeting. See our latest analysis for NKT. At a share price of DKK866.5, NKT has seen a 4.21% 1 day share price return and 8.31% 7 day share price return, while its 1 year total shareholder return of 98.01% and 5 year total...

For investors wondering whether Jyske Bank at DKK 909 still offers value or if most of the opportunity is already priced in, this article focuses squarely on what the current share price might imply. The stock has returned 6.2% over the last 7 days, while the 30-day return is a 1.5% decline and the year-to-date return sits at 3.6%, compared with a 94.1% return over the last year and 229.9% over 5 years. These moves sit against a backdrop of ongoing attention on European banks, with investors...

As European markets experience a wave of optimism amidst hopes for a shorter conflict in the Middle East, the pan-European STOXX Europe 600 Index has seen a notable rise of 3.92%. In this context, growth companies with high insider ownership can be particularly appealing as they often reflect strong internal confidence and potential resilience against market volatility.

As European markets experience a resurgence, with the STOXX Europe 600 Index climbing 3.92% amid easing concerns over Middle East conflicts, investors are increasingly drawn to dividend stocks as a source of steady income amidst inflationary pressures driven by soaring energy costs. In this climate, identifying dividend stocks that offer attractive yields can provide a reliable income stream while potentially benefiting from capital appreciation in improving market conditions.

A lackluster earnings announcement from Prime Office A/S ( CPH:PRIMOF ) last week didn't sink the stock price. Our...

Scandinavian Investment Group A/S' ( CPH:SIG ) earnings announcement last week didn't impress shareholders. While the...

EgnsINVEST Ejendomme Tyskland A/S' ( CPH:EGNETY ) recent weak earnings report didn't cause a big stock movement...

Novo Nordisk released cross trial comparison data on its oral Wegovy pill versus Eli Lilly's newly approved Foundayo pill. The company reported that oral Wegovy achieved greater weight loss and showed better tolerability than Foundayo. New patient preference data indicated a stronger preference for Wegovy's treatment profile over Lilly's oral option. For investors tracking CPSE:NOVO B, this update comes with the shares around DKK236.9 and a mixed return profile, including a 23.5% gain over...

Royal Unibrew (CPSE:RBREW) has launched a share buy-back program running from 27 February to 14 August 2026 under the EU Safe Harbour Regulation, putting capital allocation and valuation firmly in focus for investors. See our latest analysis for Royal Unibrew. At a share price of DKK535.0, Royal Unibrew has a 30 day share price return of 12.51% decline and a year to date share price return of 4.63% decline, while the 1 year total shareholder return is 1.84% decline. This suggests weaker...

The recent earnings posted by Erria A/S ( CPH:ERRIA ) were solid, but the stock didn't move as much as we expected. We...

Looking at Impero A/S' ( CPH:IMPERO ) insider transactions over the last year, we can see that insiders were net...

Park Street (CPSE:PARKST A) has reported FY 2025 first half revenue of DKK73.7m and basic EPS of DKK0.41, with the trailing twelve months showing revenue of DKK142.5m and EPS of DKK0.50 as the company trades around DKK15.70 per share. Over recent periods, revenue has moved from DKK82.3m in the first half of FY 2024 to DKK68.9m in the second half and DKK73.7m in the first half of FY 2025, while basic EPS has shifted from DKK0.10 to DKK0.07 and then to DKK0.41. This sets the scene for a closer...

Wondering whether Ørsted at DKK158.45 is starting to look like value, or still priced for high expectations? This article breaks down what the current share price may be implying. The stock has returned 9.2% over the last 7 days and 5.1% over the past month, yet over 1 year it is down 7.6% and over 5 years it is down 71.1%. This raises questions about how investors are reassessing both risk and potential. Recent attention on Ørsted has focused on its position in renewable energy and how...

Investors may be wondering whether Bavarian Nordic is attractively priced at its current level, or if the recent run has already incorporated most of the value. The stock last closed at kr197.25, with returns of 3.8% over 7 days, 2.4% over 30 days, 2.3% year to date, 30.7% over 1 year, 1.0% over 3 years, and a 31.8% decline over 5 years. Recent news coverage has focused on Bavarian Nordic's role in vaccines and biopharmaceuticals. This has kept attention on the company as investors reassess...

Aktieselskabet Schouw (CPSE:SCHO) is back in focus after recent share price moves, with the stock up 5.9% over the past week yet showing a small loss over the past month. See our latest analysis for Aktieselskabet Schouw. The recent 5.9% 7 day share price return contrasts with a modest 30 day share price decline and a slightly negative year to date performance, while the 1 year total shareholder return of 9.94% points to momentum that has been built over a longer holding period. If this kind...

At its March 25, 2026 AGM, NKT A/S approved an amendment to Article 5.2 of its Articles of Association, confirmed new employee representatives, elected Jens Due Olsen as Chair and René Svendsen-Tune as Deputy Chair, and moved to redeem all remaining securities after acquiring about 85% of the €150,000,000 issue. This combination of capital structure simplification through full security redemption and refreshed governance arrangements could influence how investors assess NKT’s financial...

Genmab (CPSE:GMAB) reports that major shareholder Orbis Investment Management Limited now holds a significant portion of its voting rights. The change in Orbis' voting stake reflects an updated picture of Genmab's shareholder structure. The disclosure highlights a material shift in ownership that may be relevant for investors tracking governance and control. Genmab focuses on developing antibody based therapies, an area that continues to attract attention as large pharma groups look for new...

Recent performance context for Novo Nordisk Novo Nordisk (CPSE:NOVO B) has drawn fresh attention after a mixed stretch in its share performance, with a small gain over the past day contrasting with weaker returns over the month and past 3 months. See our latest analysis for Novo Nordisk. At around DKK231.15 per share, Novo Nordisk’s recent 1 day share price gain contrasts with a weaker year to date share price return of about 30% and a 1 year total shareholder return decline of around 49%...

Jyske Bank (CPSE:JYSK) is back in focus after shareholders advanced plans to cancel treasury shares and reduce nominal share capital, alongside an ongoing share repurchase programme of up to DKK 3b. See our latest analysis for Jyske Bank. These capital return moves come after a mixed period for the stock. A 1-day share price return of 0.82% and 7-day gain of 1.77% contrast with a 30-day share price return of 9.01% and only slightly negative year-to-date performance. The 1-year total...

ISS buyback and dividend move into focus ISS (CPSE:ISS) has put shareholder returns firmly in the spotlight with a new share buyback programme of up to DKK 2.5b and an annual dividend of DKK 3.20 per share. See our latest analysis for ISS. That focus on shareholder returns comes as momentum has been building in the stock, with ISS’s share price at DKK234.0 and a 1 year total shareholder return of 50.89% set against a 5 year total shareholder return of 108.91%. If this kind of shareholder...